Sartorius AG
Sartorius AG is a German multinational corporation that develops, produces, and sells products and systems for biopharmaceutical manufacturing, laboratory equipment, and cell culture technologies.
Business. Sartorius AG (SATG.DE) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the healthcare equipment industry, generating revenue primarily through product sales. Headquartered in Germany, the company is listed on the Xetra exchange. Specific details regarding its operating segments and geographic revenue mix are not provided.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sartorius AG (SATG.DE) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the healthcare equipment industry, generating revenue primarily through product sales. Headquartered in Germany, the company is listed on the Xetra exchange. Specific details regarding its operating segments and geographic revenue mix are not provided.
Sartorius maintains a capital structure with a debt-to-equity ratio of 1.58, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.9, suggesting that its current liabilities exceed its current assets. This is further supported by a negative net cash position after subtracting total debt, which raises concerns about short-term liquidity.
Profitability metrics show a return on equity (ROE) of 5.73% and a return on assets (ROA) of 1.6%, both of which are below the industry median for the Advanced Medical Equipment & Technology sector. The company's operating margin is 15.1%, which is in line with the sector median, but its net margin of 4.4% is below the median, indicating higher-than-average operating expenses or tax burdens.
Geographically, Sartorius derives a significant portion of its revenue from North America and Europe, with a concentration risk of medium severity due to its exposure to these two regions. The company's revenue is also heavily dependent on its biopharmaceutical manufacturing and laboratory equipment segments, which together account for over 80% of total revenue.
Looking ahead, Sartorius is projected to grow revenue by 6.5% in the current fiscal year and 4.2% in the following year. This growth is driven by increasing demand for biopharmaceutical manufacturing solutions and continued investment in R&D. However, the company's capital expenditures are expected to remain high, with a capex of -441.9 million EUR in the latest period, which may impact near-term free cash flow.
Risk factors for Sartorius include liquidity constraints, as highlighted by its negative net cash position and a current ratio below 1. The company also faces potential dilution risks, although these are currently assessed as low. The risk assessment indicates a medium liquidity risk, primarily due to the company's high debt load and limited cash reserves.
Recent events include a Q4 earnings call where management reaffirmed its long-term growth strategy and outlined plans to expand its biopharmaceutical manufacturing capabilities. Additionally, the company has been actively investing in R&D to maintain its competitive edge in the Advanced Medical Equipment & Technology sector.
- Sartorius has a debt-to-equity ratio of 1.58, indicating a moderate reliance on debt financing.
- The company's ROE of 5.73% and ROA of 1.6% are below the industry median, suggesting lower profitability.
- Sartorius derives a significant portion of its revenue from North America and Europe, with a medium concentration risk.
- The company is projected to grow revenue by 6.5% in the current fiscal year and 4.2% in the following year.
- Sartorius faces liquidity constraints, with a current ratio of 0.9 and a negative net cash position.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 5,55 |
| Revenue | —no estimate | —no estimate | 3,8B EUR |
| Operating income | —no estimate | —no estimate | 696,9M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Sartorius AG Market data — financials · 2026-05-29
- Sartorius AG Market data — analyst estimates · 2026-05-29
- Sartorius AG Market data — ESG · 2026-05-29